|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Prostate Cancer Treatment in the USA
Datamonitor, Sep 2004, Pages: 441
Introduction
Prostate cancer is the most common male malignancy in Western countries. Increasing usage of screening and changes in treatment practice means companies will have to adapt to exploit the market. We have Prostate Cancer Insight details physician opinion of currently available products and disease management practice and what they require in the future.
Scope
Quantitative treatment data from 80 physicians from the US
Qualitative feedback on key findings and future trends in the treatment of prostate cancer and the management of disease and treatment side effects
Coverage of the hot topics affecting current treatment patterns, from the impact of IMRT on brachytherapy to the increasing use of bisphosphonates
A strong future focus on key issues, including the increasing use of third generation cytotoxics in HRPC
Highlights
AstraZeneca is promoting Casodex monotherapy heavily in non-metastatic disease as an alternative to an LHRH agonist. Approval for Casodex monotherapy has been delayed in some markets, but physicians are already prescribing off-label, especially in patients with dementia, a condition that can be exacerbated by the use of LHRH agonists.
Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis Taxotere show much greater efficacy and usage of this combination is already significant.
Reasons to Purchase
Identify hot topics and key issues for practicing prostate cancer specialists the questions they really want answered
Predict future trends in the treatment of prostate cancer and how to capitalize on forthcoming changes in treatment practice
Plan product development to fill prostate cancer market niches as defined by practicing physicians
Customers who bought this item also bought
Treatment Algorithms 2001: Prostate Cancer
Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Stakeholder Insight: Local and Locally Advanced Prostate Cancer
Prostate Cancer Insight - Profiting From Changing Treatment Patterns
Cancer Drug Discoveries: What the Future Holds: Prostate Cancer Chapter
Prostate Cancer Therapeutics - Global Strategic Business Report
Stakeholder Insight: Prostate Cancer Treatment and Commercial Issues
Prostate Cancer Opinion Leader Forum, 2002
Drugs of Tomorrow 2000: Prostate Cancer - Hormonals and Beyond
Strategic Perspectives: Prostate Cancer - Issues in Second-line, Brachytherapy and Hormone-Refractory Prostate Cancer Treatments
Prostate Cancer Therapeutics - A Global Market Perspective
|
|
|
|
